Edition:
United States

Exact Sciences Corp (EXAS.OQ)

EXAS.OQ on NASDAQ Stock Exchange Capital Market

69.49USD
4:00pm EDT
Change (% chg)

$-0.47 (-0.67%)
Prev Close
$69.96
Open
$68.78
Day's High
$70.02
Day's Low
$68.43
Volume
556,432
Avg. Vol
692,281
52-wk High
$71.55
52-wk Low
$32.49

Chart for

About

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA)... (more)

Overall

Beta: 1.01
Market Cap(Mil.): $8,353.69
Shares Outstanding(Mil.): 121.90
Dividend: --
Yield (%): --

Financials

  EXAS.OQ Industry Sector
P/E (TTM): -- 241.68 34.14
EPS (TTM): -2.05 -- --
ROI: -32.42 -5.91 13.17
ROE: -48.92 -7.75 15.14

UPDATE 1-American Cancer Society recommends earlier colorectal cancer screening

May 30 The American Cancer Society on Wednesday recommended that people at average risk of colorectal cancer start regular screening at the age of 45 rather than at 50, at a time when studies show a rise in cases of the disease among younger individuals.

May 30 2018

BRIEF-Exact Sciences Says CEO Kevin T. Conroy's 2017 Total Compensation Was $13.3 Million

* EXACT SCIENCES CORP SAYS CEO KEVIN T. CONROY'S 2017 TOTAL COMPENSATION WAS $13.3 MILLION – SEC FILING Source : https://bit.ly/2w2gEbC Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 30 2018

BRIEF-Exact Sciences reports Q1 Loss Per Share of $0.33

* Q1 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S

Apr 26 2018

BRIEF-Mark Stenhouse To Join Exact Sciences As President, Cologuard

* MARK STENHOUSE TO JOIN EXACT SCIENCES AS PRESIDENT, COLOGUARD

Mar 20 2018

BRIEF-Exact Sciences Q4 Loss Per Share $0.18

* ANTICIPATES COMPLETED COLOGUARD TEST VOLUME OF 900,000-920,000 TESTS DURING 2018.

Feb 22 2018

BRIEF-Exact Sciences announces upsize, pricing of $600 mln of 1 pct convertible senior notes due 2025

* EXACT SCIENCES ANNOUNCES UPSIZE AND PRICING OF $600 MILLION OF 1.0% CONVERTIBLE SENIOR NOTES DUE 2025

Jan 11 2018

BRIEF-Exact Sciences Offers $500 Mln Convertible Senior Notes Due 2025

* EXACT SCIENCES ANNOUNCES OFFERING OF $500 MILLION CONVERTIBLE SENIOR NOTES DUE 2025 Source text for Eikon: Further company coverage:

Jan 11 2018

BRIEF-Exact Sciences Says "Comfortable" With Current 2018 Consensus Revenue Estimate Of Around $417 Mln

* EXACT SCIENCES CORP SAYS "COMFORTABLE" WITH CURRENT 2018 CONSENSUS REVENUE ESTIMATE OF AROUND $417 MILLION Source text for Eikon: Further company coverage:

Jan 10 2018

Competitors

  Price Chg
Quest Diagnostics Inc (DGX.N) $110.67 +0.32
Epigenomics AG (ECXn.F) €2.58 +0.22
GeneNews Ltd (GEN.TO) $0.08 -0.00

Earnings vs. Estimates